The Prognostic Value of Preoperative Participation in Activities of Daily Living on Postoperative Outcomes Following Lumbar Discectomy

Leonard, Dana A.; Deering, Rachel M.; Ramachandran, Ravi P.; Hess, Kathryn A.; Harris, Mitchel B.; Bono, Christopher M.

doi:10.1016/j.spinee.2014.08.176

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An association already exists among comorbidity, number of medications taken, and worse outcome parameters for other critical patients (eg, those with ischemic stroke). 12 In this study, we demonstrated a highly significant association between preoperative ADL value and mortality for the first time in patients undergoing urologic surgery, as is already established in orthopedics, 19 strongly highlighting the need for CGA. Another main finding was the significant association between low postoperative ADL value and length of hospital stay, according to the existing knowledge of urologic surgical treatment.…”

Section: Original Researchmentioning

confidence: 56%

“…Most patients (63 of 66; 95%) accepted the germline testing and high satisfaction rates were achieved among both oncologists and patients. 19 A provider-led germline testing model in the Veterans Affairs health care system was also evaluated. Patients with…”

Section: Delivery Care Models For Germline Testingmentioning

confidence: 99%

“…17,18 HER2 amplification has also been implicated as a driver of primary resistance to EGFRi therapy. 18,19 Similar to BRAF, the rarity of HER2 amplification in mCRC has limited the ability to make definitive conclusions regarding its role in EGFR resistance. Nonetheless, HER2 amplification is associated with significantly worse outcomes in patients treated with EGFR antibodies with or without cytotoxic chemotherapy.…”

Section: Yoshino Is Director Of the Department Of Gastroenterology Andmentioning

confidence: 99%

See 2 more Smart Citations

Value of Geriatric Assessment in Patients With Genitourinary Carcinoma

et al. 2021

View full text Add to dashboard Cite

EGFR, epidermal growth factor receptor; mNSCLC, metastatic non-small cell lung cancer. BRIEF SUMMARY OFPRESCRIBING INFORMATION EXKIVITY ™ (MOBOCERTINIB) WARNING: QTc PROLONGATION and TORSADES DE POINTES • EXKIVITY can cause life-threatening heart rate-corrected QT (QTc) prolongation,including Torsades de Pointes, which can be fatal, and requires monitoring of QTc and electrolytes at baseline and periodically during treatment. Increase monitoring frequency in patients with risk factors for QTc prolongation [see Warnings and Precautions (5.1)]. • Avoid use of concomitant drugs which are known to prolong the QTc interval and use of strong or moderate CYP3A inhibitors with EXKIVITY, which may further prolong the QTc [see Warnings and Precautions (5.1), Drug Interactions (7.1, 7.3)]. • Withhold, reduce the dose, or permanently discontinue EXKIVITY based on the severity of QTc prolongation [see Dosage and Administration (2.3)]. 1 INDICATIONS AND USAGE EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1)], whose disease has progressed on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). 2 DOSAGE AND ADMINISTRATION 2.1 Patient Selection Select patients with locally advanced or metastatic NSCLC for treatment with EXKIVITY based on the presence of EGFR exon 20 insertion mutations [see Clinical Studies (14)]. Information on FDA-approved tests is available at: http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosage The recommended dosage of EXKIVITY is 160 mg orally once daily until disease progression or unacceptable toxicity. Take EXKIVITY with or without food [see Clinical Pharmacology 12.3], at the same time each day. Swallow EXKIVITY capsules whole. Do not open, chew or dissolve the contents of the capsules.If a dose is missed by more than 6 hours, skip the dose and take the next dose the following day at its regularly scheduled time.If a dose is vomited, do not take an additional dose. Take the next dose as prescribed the following day. Dosage Modifications for Adverse ReactionsEXKIVITY dose reduction levels for adverse reactions are summarized in Table 1. USE IN SPECIFIC POPULATIONS 8.1 PregnancyRisk Summary Based on findings from animal studies and its mechanism of action [see Clinical Pharmacology (12.1)], EXKIVITY can cause fetal harm when administered to a pregnant woman. There are no available data on EXKIVITY use in pregnant women. Oral administration of mobocertinib to pregnant rats during the period of organogenesis resulted in embryolethality (embryo-fetal death) and maternal toxicity at plasma exposures approximately 1.7 ...

show abstract

Section: Original Researchmentioning

confidence: 56%

Section: Delivery Care Models For Germline Testingmentioning

confidence: 99%